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ABSTRACT 
Interaction of Nitric Oxide and Muscle Contraction in Adenosine-induced Muscle 
Vasodilation in Humans 
Amanda Rossi 
Adenosine (ADO) is one of several endogenous substances known to mediate 
muscle vasodilation during exercise. The purpose of this study was to examine 1) 
the role of nitric oxide (NO) in ADO-mediated vasodilation; 2) the magnitude of 
muscle blood flow (MBF) responses to ADO infusion during exercise; and 3) the 
influence of ADO in regulating heterogeneous MBF distribution. In healthy, young 
participants (N=14), local MBF was measured using near-infared spectroscopy 
and indocyanine green (ICG) dye at two locations on the vastus lateralis (VL). 
Cardiac output was quantified using a dye-dilution technique with ICG dye. 
Participants were tested at rest and during 1-leg knee extension exercise (25W) 
under different conditions: control, ADO infusion (150mg*kg body mass"1#min"1) 
and ADO+NO blockade (L-NMMA; 1mg»kg body mass"1'min"1). At rest and 
exercise, we found that mean VLBF increased from control to ADO and 
decreased significantly from ADO to ADO+L-NMMA infusion; exercising BF 
values were always significantly higher than at rest. Additionally, with ADO 
infusion, a peak increase in oxy-hemoglobin concentration (02Hb) was reached 
within 2 minutes of initiating infusion; however the magnitude differed between 
iii 
muscle regions, indirectly indicating ADO-induced metabolic heterogeneity. O2HD 
subsequently decreased over time, reaching a stable level at 5 min. Also, we 
observed that when MBF is elevated through ADO infusion, usual exercise-
mediated vasodilator signals are not subsequently down-regulated during 
contraction demonstrating a lack of autoregulation. We conclude that NO does 
play a role in mediating ADO-induced vasodilation and there is a lack of 
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In the field of cardiovascular physiology, a major emphasis is placed on 
research aimed at elucidating what factors regulate blood flow to skeletal 
muscle during exercise. It is known that neural, humoral, metabolic and 
mechanical factors contribute to the regulation of this complex system 
(Olsson, 1981; Segal, 2005). Blood functions to transport and deliver oxygen, 
nutrients and hormones to the body's tissues and subsequently remove a 
multitude of metabolic by-products. The former role is indeed an important 
physiological function since almost all cells in the body require oxygen for 
viability. All tissues are capable of regulating their own local blood flow in 
proportion to their own metabolic needs (Wolff, 2007). During exercise, for 
example, blood flow is increased in the active skeletal muscle in order to 
accommodate increases in metabolic activity (Saltin, 1985). Simultaneously, 
blood is shunted away from other organs, such as the kidneys and spleen 
(Rowell, 1986), enhancing the efficiency with which the cardiovascular system 
can supply blood to the tissues with a higher metabolic demand. 
Blood flow increases as a result of vasodilation, which is simply an increase in 
the inner diameter of blood vessels. Several mechanisms regulate the degree 
of muscle vasodilation, and therefore how blood flow is controlled. In this 
review, various mechanisms of blood flow regulation; namely the vascular 
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myogenic reflex, autonomic sympathetic neural signaling and the muscle 
pump effect will be briefly described, followed by a more detailed discussion 
of the main focus; understanding the actions of and interactions between 
putative biochemical substances currently thought to play a major role in 
skeletal muscle vasodilation during exercise. 
The myogenic mechanism of vascular control maintains that tension 
receptors present in arterial and arteriolar walls (which contain smooth 
muscle) sense and respond to pressure exerted on the vascular wall, induced 
by luminal stretch or abluminal compression forces induced by muscle 
contraction (Delp, 1999; Guyton & Hall, 2000). The myogenic response is 
thought to be one of the key regulators of basal vascular tone (Davis & Hill, 
1999). In general, the in-vivo myogenic response is evoked by 1) a rapid and 
transient stretch of the vessel wall during increased pulsatile flow that 
enhance transmural pressure, resulting in a vascular smooth muscle 
contractile response (Davis & Hill, 1999; Schubert & Mulvany, 1999) which is 
considered protective against over distention, and 2) a mechano-chemical 
response via gap junctions to effect conducted vasodilation (Figueroa & 
Duling, 2009) when the vessel is compressed abluminally by muscle 
contraction. The muscle pump system is another proven mechanism whereby 
rhythmic contractions of skeletal muscle propel blood perfusing the muscle 
vasculature into the venous system, therefore assisting venous return to the 
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right heart, which ultimately increases cardiac output via the Frank-Starling 
mechanism and hence systemic blood flow is enhanced (Delp, 1999). 
Another regulator of vascular conductance during exercise is the sympathetic 
branch of the autonomic nervous system (SNS). It has been proposed that 
through sympathetic cholinergic action, the SNS has the ability to induce 
vasodilation; however this effect is minor and inconsequential for exercise 
induced hyperemia. Conversely, alpha adrenergic signals cause vessels to 
vasoconstrict (Buckwalter et al., 1997, 1998a; Buckwalter et al., 1998b; 
Buckwalter & Clifford, 1999) and account in large part for the redistribution of 
blood flow away from inactive vascular beds during exercise, increasing the 
direction of the central blood volume to the most metabolically active tissues 
(Christensen & Galbo, 1983). The influence of the SNS on preferentially 
enhancing blood flow to contracting muscle is exemplified by studies showing 
that exercise induces large increases in sympathetic outflow systemically 
measured by plasma norepinephrine levels and norepinephrine spillover from 
vessels draining major organ systems (Christensen & Galbo, 1983; 
Leuenberger et al., 1993) and direct recordings of sympathetic discharge from 
sympathetic nerves measured by microneurography (Seals, 1989). In actively 
contracting muscle, local sympatholytic signals emitted from the skeletal 
muscle act to curtail the vasoconstrictive activity of the SNS (Hansen et al., 
2000), whereas in tissues and organs which remain inactive (at a stable 
metabolic state) the release of sympatolytic mediators also remain constant, 
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and in this case the sympathetically mediated vasoconstriction will 
predominate. Precisely how this coordination is manifested is subject of 
debate and is in part based on the not so clearly defined distribution patterns 
of alpha 1 and 2 receptors for the maintenance of vascular tone and the 
impact of motor unit recruitment linking metabolic events to oppose 
vasoconstriction (Delp, 1999; Segal, 2005). 
During the contraction phase of dynamic exercise and during isometric 
muscle contractions, blood flow may be impeded as a result of the 
mechanical compression imposed on the vessels. Laughlin (1987) proposed 
several mechanisms by which the skeletal muscle contraction-relaxation cycle 
may produce or contribute to the exercise hyperaemia; this is known as the 
muscle pump. Firstly, the muscle contraction causes venous emptying as a 
result of the direct compression on the venous vessels. Secondly, it was 
suggested that blood may be propelled through a muscle by a 'milking' action 
produced, again, as a result of the mechanical constriction cause by muscle 
contraction. Additionally, venous filling is facilitated by very low to negative 
luminal pressures in the veins produced by muscle relaxation, thus increasing 
the pressure gradient across the skeletal muscle vascular bed and hence 
driving flow across the muscle. Muscle contraction may also pass on kinetic 
energy to blood flow; however the accuracy of this theorem is not yet known 
(Laughlin, 1987). Tschakovsky and Sheriff (2004) put forth the notion that 
mechanical disruption of the vascular smooth muscle cells may dislocate the 
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cross-bridging, resulting in vasodilation. Also, the authors speculate that 
negative venous pressures may 'charge' arterioles, increasing pressure 
higher than normal during contraction, and subsequently upon relaxation this 
discharge pressure would drive the blood into the venous circulation. 
As mentioned previously, the magnitude of blood flow to organs and tissue 
regions follow closely with the metabolic needs of each tissue, which implies 
there exists a system of communication between signals of tissue metabolism 
and signals controlling vascular tone, which defines tissue 0 2 delivery. A 
prevailing argument is that this matching of blood flow to metabolic demands 
results from the production of local vasodilatory metabolites. Sources of these 
dilator substances include the endothelial lining of the vessels, the vascular 
smooth muscle, and possibly skeletal muscle itself (Clifford & Hellsten, 2004). 
There are several different substances which are known to increase in the 
vicinity of the interstitial space which is the interface between the vessel and 
muscle tissue. Examples of these substances considered to play a role in 
regulating vascular tone include nitric oxide (NO), prostacyclin (PGI2), 
adenosine (ADO), adenosine triphosphate (ATP) and epoxyeicosatrienoic 
acids (EETs), among others. 
The vascular endothelium, which is in direct contact with the blood, is of 
particular interest in cardiovascular physiology because of abundant evidence 
for its major role in sensing and responding in a mechano-metabolic fashion 
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to signals induced luminally to alter flow dynamics, and by local diffusible 
metabolic signals released from adjacent tissues. When stimulated by shear 
stress endothelial cells produce both NO, which will be discussed later in this 
review, and PGI2 (Boushel, 2003). Prostaglandins, and more specifically 
PGI2, which is formed from cyclooxygenase oxidation of arachidonic acid in 
the lipid bilayer of the vascular wall by activation of phospholipase A2 and 
released from the endothelial cell membrane inward to elicit vasodilation of 
underlying smooth muscle, are also considered important endothelial 
vasoactive substances (Boushel etal., 2004). The skeletal muscle may also 
be a source of PGI2 (Clifford & Hellsten, 2004). Concentrations of PGI2 have 
been shown to increase in the circulation (Wilson & Kapoor, 1993) and in 
muscle interstitial fluid (Young & Sparks, 1980) during exercise. Additionally, 
based on studies conducted by various groups of researchers, it has been 
confirmed that PGI2 does indeed influence vascular tone during rest, reactive 
hyperaemia and during exercise recovery periods (Boushel, 2003). The 
vascular endothelium also produces an endothelial derived hyperpolarizing 
factor (EDHF), which is thought to be a member of the EETs. EETs are also 
formed from arachidonic acid, specifically through cytochrome P-450 
epoxygenase pathways (Boushel, 2003) and have been shown to induce 
vasodilation of coronary microvessels in dogs (Clifford & Hellsten, 2004). 
Studies examining the involvement of the EETs cascade on exercise 
hyperaemia have found reduced muscle blood flows during exercise when 
pharmacologically blocking the EET pathway with sulphaphenazole; however, 
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significant decreases in blood flow are only noted when EET blockade is 
combined with nitric oxide synthase (NOS) inhibition with L-NMMA (Passauer 
et al., 2003). The capacity for EETs to exert a major independent role in 
muscle vasodilation is obscured by the inability to experimentally detect either 
12-13 or 14-15 EET isoforms in the interstitial fluid samples collected from 
human muscle (Lattereur et al., In preparation). 
Also derived from the endothelium are ADO and NO, both of which are 
considered to be very important vasodilators. The remainder of this review will 
be dedicated to the role of these two latter vasodilation mediators during 
exercise and how they may potentially interact with each other to co-ordinate 
blood flow regulation by their actions on the vasculature. 
Adenosine 
Evidence for ADO formation and action in the skeletal muscle extracellular 
matrix and vascular endothelium has greatly contributed to fortifying a role for 
ADO as one of the major vasodilators. Previously, it was thought that ADO 
was produced from the degradation of adenine nucleotides (adenosine 
triphosphate (ATP), adenosine diphosphate (ADP), adenosine 
monophosphate (AMP)) within contracting skeletal muscle. More recently, it 
has been shown that in fact ADO is formed extracellularly from AMP by the 
membrane bound ecto-enzyme 5'-nucleotidase (ecto-5'N) (Cheng et al., 
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2000). ADO can be produced both intra- and extracellularly and although 
other non-specific phosphotases are also capable of de-phosphorylating AMP 
to ADO, it was shown that ecto-5'N is the main enzymatic pathway in its 
formation. The rate of ADO production was found to be dependent on pH. 
Subsequently, other factors including 1) affinity of ecto-5'N for AMP and 2) 
AMP concentration were found to be important driving forces for ADO 
formation under acidic (1 & 2) and alkalinic (2 only) conditions (Cheng et al., 
2000). Further support for the extracellular formation of ADO was reported by 
Lynge et al. (2001) who showed that inhibition of ecto-5'N resulted in a 70% 
reduction in the rate of extracellular ADO accumulation when compared with 
control cells. It is true that ADO can still be formed in locations other than the 
extracellular space; however, based on this evidence, it has been accepted 
that the extracellular space is one of the key sites for ADO production. 
Another important piece of evidence which supports ADO being a potent 
vasodilator candidate is the location where ADO exerts its action; the 
vasculature itself. Lynge and Hellsten (2000) were the first to localize ADO 
receptors in skeletal muscle and vasculature cells. Using 
immunohistochemical techniques, the researchers identified A2A and A2B 
receptors in the cytosol and sarcolemma of skeletal muscle cells biopsied 
from human quadriceps muscles. Furthermore, A^ A2A and A2B receptors 
were found to co-exist on the membrane of both smooth muscle and vascular 
endothelial cells. Of importance is the fact that these results were obtained 
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from human skeletal muscle tissue, and were supported by parallel cell 
culture studies (Lynge & Hellsten, 2000). Therefore, these findings are 
specific to humans and transferability/generalization of the results between 
species is not a concern. Missing still is a full understanding of the precise 
physiological role these receptors may play. 
Recent work has shown that ADO plays some role in regulating the 
distribution of microvascular blood flow during exercise in humans. A Finnish 
team used positron emission tomography (PET) to quantify blood flow while 
infusing theophylline, a competitive non-specific ADO receptor antagonist, 
and found that blockade increased blood flow heterogeneity (Heinonen et al., 
2007). Additionally, using novel biological tracers which specifically bind to 
A2A ADO receptors, it has been shown that the density of A2A receptors is 
markedly increased in the myocardium of trained athletes compared to 
untrained individuals (Heinonen et al., 2008). 
ADO has been shown to accumulate in human skeletal muscle during 
contraction. Hellsten et al. (1998) were the first to report interstitial ADO 
concentrations in human skeletal muscle. From their analysis, resting 
interstitial fluid ADO concentration was measured to be 220 ± 100 nmol/L at a 
corresponding femoral artery blood flow of 0.19 ± 0.02 L/min. The authors 
also showed that interstitial ADO concentration increased with muscle 
contraction, which in this case was achieved using the dynamic knee 
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extension model (Andersen & Saltin, 1985). A significant increase in ADO 
concentration was seen between rest and exercise; even at a low intensity. 
Moreover, the interstitial fluid concentrations of ADO increased at a rate 
associated with the observed increases in blood flow and exercise intensity 
(Hellsten etal., 1998; Langberg etal., 2002). These findings clearly 
demonstrate that ADO does indeed accumulate with contraction in human 
skeletal muscle and more importantly that this increase in ADO concentration 
is directly related to augmentation of blood flow and exercise intensity. 
Studies quantifying the blood flow response to ADO infusion and blockade 
are also meaningful when examining the role of ADO as one of the key 
vasodilator substances. Radegran and Calbet (2001) infused theophylline and 
found that the hyperaemic response to exercise was approximately 20% 
lower under ADO receptor blockade when compared to control conditions. 
Several animal studies have shown similar results, where the hyperaemic 
response is significantly diminished with specific ADO receptor blockade; Ai 
receptor antagonist DPCPX, A2A receptor antagonist ZM 241385 (Bryan & 
Marshall, 1999; Ray & Marshall, In press-a). Meanwhile, adenosine infusion 
revealed the opposite effect. In fact, infusion of ADO at submaximal exercise 
intensities elicited blood flow values previously seen at peak effort. 
Continuous infusion of adenosine (up to 220 ug kg body weight"1 min"1) into 
the femoral artery of healthy humans at rest increases leg blood flow to peak 
values of -6-8 L min"1 measured by ultrasound Doppler (Radegran & Calbet, 
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2001). Using constant infusion thermodilution, the vasodilatory response of 
similar subjects to infusion of both (maximal dose response) adenosine (150 
ug.kg body weight"1 min"1) and ATP (80 ug kg"1 body weight"1 min"1) elicit leg 
blood flows of similar levels (Calbet et al., 2006). The findings reported 
therefore demonstrate an essential role for endogenous ADO in sustaining 
hyperaemic response during exercise. Furthermore, the significant increase in 
blood flow up to maximal levels brought forth the concept that there exists a 
vasodilator reserve which is potentially mediated by ADO. 
It also appears that ADO plays a role in peripheral vasodilation during 
systemic hypoxia. ADO has the capacity to dilate both arterioles and venules 
under hypoxic conditions in rats (Mian & Marshall, 1991). Using microdialysis 
to collect interstitial fluid samples and applying plethysmography to measure 
blood flow in humans, MacLean etal. (1998) showed that interstitial 
concentrations of ADO significantly increased from 0.44±0.08 ^mol-L"1 to 
1.03±0.15 lamol-L"1 and 0.85±0.09 ^mol-L"1 at 15 and 30 minutes of hypoxia, 
respectively. These values have been similarly replicated in recent studies 
(Lattereur et al., In preparation). 
ADO was also proposed to be one of the key regulators of insulin-mediated 
vasodilation. However, after much debate arose from animal studies, Dela 
and Stallknecht (1999) showed that there was no change in ADO 
concentration when comparing interstitial fluid samples during rest, under 
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control and hyperglycaemic and hyperinsulinemic conditions in humans. This 
study was conducted in both healthy and spinal cord injury patients, so as to 
eliminate any controversial effects of ADO or adenine nucleotides potentially 
released from nerve terminals. However, in a follow-up study it was shown 
that combined infusion of ADO + insulin increases muscle blood flow to a 
level higher than either substance alone, indicating a synergistic action of 
these substances for increasing muscle blood flow (Scheede-Bergdahl etal., 
Submitted). Other studies have shown a great deal of support for ADO as a 
regulator of the coronary circulation (Berne, 1980). However, most of these 
studies have been conducted on animals. Nonetheless, it is quite clear that 
ADO does play a role here with comparable quality evidence to that seen in 
human skeletal muscle concerning ADO formation in the myocardium and 
ADO action (Berne, 1980). 
Nitric Oxide 
NO is also considered to be a ubiquitous regulator of tissue vasodilation. 
Nitric oxide synthase (NOS) is the main catalyst of NO production and is 
found in several different isoforms; for example, endothelial (e), neuronal (n) 
and inducible (i) NOS. NOS acts to catalyse the hydrolysis of L-arginine to L-
citrulline and NO in the presence of oxygen (Boushel, 2003). nNOS and 
uNOS, the skeletal muscle-specific isoform, were found to be located in the 
sarcolemma and cytosol of skeletal muscle cells. Their presence is highly 
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associated with mitochondrial density and also dependent on fiber type. 
Greater quantities of nNOS have been observed in type I muscle fibers in 
comparison to type II fibers (Stamler & Meissner, 2001). In human skeletal 
muscle, eNOS is only found in the vascular endothelium, as opposed to 
observations in rats, where eNOS has also been located within type I muscle 
fibers (Stamler & Meissner, 2001). 
There are both similarities and differences between NOS isoforms regarding 
which factors regulate their activity. All isoforms can be transcriptionally 
regulated by hypoxia and upregulated by cytokines (Stamler & Meissner, 
2001). Increased nNOS expression is seen with crush injuries, muscle activity 
and ageing; and decreased after denervation. Vascular eNOS is upregulated 
by shear stress. Chronic exercise can also promote vascular and skeletal 
muscle eNOS expression (Stamler & Meissner, 2001). NOS expression and 
hence activity is also regulated by phenotypic factors (myotube vs. fused 
myoblast), in addition to other developmental factors beyond the scope of this 
review (Stamler & Meissner, 2001). These factors influencing NOS 
expression, however, are important because ultimately, they are the 
regulators of NO production. 
It is well known that NO regulates basal vascular tone. It does so via 
activation of guanylate cyclase in smooth muscle cells of the vasculature 
(Clifford & Hellsten, 2004). NG-monomethyl-L-arginine (L-NMMA) a non-
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specific, competitive NOS inhibitor has been frequently used in studies to 
determine the role of NO for tissue vasodilation. During resting conditions 
under NOS blockade, vascular resistance is increased significantly (Gilligan 
etal., 1994), leading to increased mean arterial pressure (Jimbo etal., 1994). 
Significant physical reduction of vessel diameter has been shown in animal 
models measured by in-vivo microscopy and isolated microvessels ex-vivo 
with NOS blockade (Clifford & Hellsten, 2004). The rate of blood flow, as 
measured by plethysmography in humans is also decreased at rest when L-
NMMA is infused (Gilligan etal., 1994). Moreover, this decrease has been 
shown to be dose-dependent (Vallance etal., 1989) and reversible when L-
arginine (the substrate from which NO is formed) is infused either after 
cessation or in combination with infusion of L-NMMA (Vallance etal., 1989; 
Tagawa etal., 1994). L-NMMA has also been used in studies examining the 
coronary vessels. During resting conditions, it has been shown that a 
significant decrease in vessel diameter and increase in vascular resistance 
occurs (Duffy et al, 1999) as well as significant decreases in blood flow 
(Clifford & Hellsten, 2004). 
Several studies have found a lack of evidence to support NO in an obligatory 
role contributing towards the initiation or maintenance of reactive hyperemia 
in response to cuff occlusion. Peak hyperaemic flow after 3 and 10 minutes of 
arterial occlusion did not decrease in response to intra-arterial infusion of L-
NMMA (Tagawa ef al., 1994). Engelke et al. (1996) also used a forearm 
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occlusion model to elicit hyperaemic conditions, in combination with L-NMMA 
administration and found that NO was not essential for reactive hyperaemia. 
Taken together with other data collected in this study concerning PGI2) the 
authors concluded that endothelial factors do play some role in reactive 
hyperaemia, however, the endothelial component of vasodilation can only 
account for part of the large increase in blood flow observed. Other 
metabolites, such as H+, K+, PO4, PGI2, ATP, ADO and myogenic factors 
(Boushel, 2003; Clifford & Hellsten, 2004) are thought to contribute more to 
reactive hyperaemia than NO. 
Whether or not the same can be said for NO during exercise conditions is still 
questionable. There is a lack of consistency amongst findings concerning 
hemodynamic changes induced by L-NMMA infusion between rest, exercise 
and recovery from exercise. Mean arterial pressure has been found to either 
remain the same or increase during L-NMMA infusion (Gilligan etal., 1994; 
Koller-Strametz etal., 1998). Discrepancies were also seen between studies 
measuring vascular resistance during NO blockade (Gilligan et ai, 1994; 
Koller-Strametz etal., 1998). In addition, decreased blood flow has also been 
observed between control and L-NMMA infusion during exercise (Endo etal., 
1994; Gilligan etal., 1994); however authors have attributed this decrease to 
the fact that basal blood flow is lowered with L-NMMA infusion (Endo et ai, 
1994) prior to beginning exercise. Hence, evidence exists both to support and 
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contradict NO's role as an independent vasodilator during exercise, and most 
researchers have attributed only minimal involvement of NO during exercise. 
When we consider studies that have blocked NO production by 
pharmacological NOS inhibitors in addition to other vasodilator substances 
(i.e. multiple blockade), we see that there is a significant reduction in blood 
flow to the working muscles during exercise. Boushel et al. (2002) were the 
first to report the results of double vasodilator blockade; NO and PG with L-
NMMA and indomethacin, respectively. It was shown that microvascular 
blood flow was significantly reduced during exercise under double blockade 
when compared to control conditions. The report reinforces the concept of 
synergy and redundancy amongst vasodilators. Mortensen et al. (2007) also 
observed similar blood flow decreases during double blockade; however 
additional blockade of EDHF, by inhibiting calcium activated K+ (Kca) 
channels with tetraethylammonium chloride (sulphaphenazole), revealed no 
further decrease in blood flow. The authors therefore concluded that EDHF is 
not able to compensate for reduced NO and PG production (Mortensen et al., 
2007). This evidence indicates that NO does indeed play a part in exercise 
hyperaemia; however, other vasodilation mediators have the capacity to 
compensate for the blocked NO during exercise, displaying the redundancy 
between mechanisms. 
It seems NO also exerts some role in maintaining vasodilation post-exercise. 
L-NMMA has been shown to attenuate peak flow and limit decreases in 
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vascular resistance immediately post-exercise (Endo et a/., 1994; Gordon et 
al., 2002). L-NMMA also significantly reduced hyperaemic volume post-
exercise (Gordon etal., 2002). 
Interactive Mechanisms 
As previously mentioned, there exists redundant vasodilator pathways for 
regulating muscle blood flow (Boushel & Kjaer, 2004). Therefore, there must 
be some mechanism(s) by which the synergistic actions of the metabolically 
derived dilation mediators are regulated. It is possible that they interact via 
second messenger systems or even through feed forward or feed back loops. 
In keeping with the focus of this review, the mechanism proposed for the 
interaction between ADO and NO will be discussed. 
Earlier it was shown that ADO does indeed have some influence on vascular 
tone based on measurements of blood flow and interstitial ADO concentration 
under different conditions. However, these studies tell little about how ADO 
exerts its effects at the cellular level. A reductionist approach is necessary to 
determine the means by which ADO provokes a vasodilatory response. In 
doing so, it has been uncovered that both A-\ and A2A ADO receptors located 
on the endothelium are important in the ADO-mediated vasodilation cascade 
(Olsson & Pearson, 1990; Danialou etal., 1997; Ray & Marshall, 2006). Ai 
receptor agonists induced concentration dependent dilation of rat 
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diaphragmatic arterioles (Danialou etal., 1997). Moreover, Ai antagonists 
both attenuated ADO-induced dilation (Danialou etal., 1997) and reversed 
hemodynamic changes and vasodilatory effects generated by Ai selective 
agonists (Bryan & Marshall, 1999). Stimulation and inhibition of A2A receptors 
showed similar results as those seen for Ai ADO receptors (Danialou et a/., 
1997; Bryan & Marshall, 1999). However, it seems that in hypoxia, Ai 
receptors contribute more than A2A receptors (Danialou et ai, 1997; Bryan & 
Marshall, 1999), whereas during normoxia both receptor types contribute 
equally to ADO induced vasodilation (Bryan & Marshall, 1999). In pig 
coronary arteries Ai agonists, but not A2A agonists, were able to mimic ADO-
generated dilation. Conversely, Ai receptor antagonist inhibited vasodilation 
resulting from ADO infusion, and A2A receptor antagonist were ineffective 
(Dart & Standen, 1993). More recently, Ray and Marshall (In press-a) have 
suggested that in the rat hindlimb during both twitch and tetanic muscle 
contractions ADO derived from the muscle builds up in the interstitium 
regardless of the nature of the contraction imposed. Moreover, the authors 
state that based on the data collected, the released ADO acts directly on the 
vascular smooth muscle A2A receptors; however the contribution towards 
exercise hyperaemia is greater for tetanic contractions. This remains to be 
investigated in humans. 
ADO receptors are coupled to ATP sensitive K+ (KATP) channels in the 
vascular endothelium. It has been shown that vasodilation responses induced 
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by Ai receptor agonists can be attenuated with simultaneous administration of 
KATP channel blockers (Nakhostine & Lamontagne, 1993; Danialou et ai, 
1997) or even cause vasoconstriction (Nakhostine & Lamontagne, 1993). 
Kleppisch and Nelson (1995) showed that when arterial smooth muscle KATP 
channels are blocked ADO-induced signalling is inhibited. Additionally, 
electrophysiological recordings revealed that A2A agonists were capable of 
triggering KATP channel inhibitory currents; however Ai agonists were not 
effective (Kleppisch & Nelson, 1995). 
When ATP sensitive K+ channels are stimulated in endothelial cells causing a 
K+ efflux, the membrane becomes hyperpolarized (i.e. increased negative 
charge within the cell and a corresponding extracellular positive membrane 
charge). This creates an electrochemical force for Ca2+ influx which initiates 
intracellular activation of cAMP (Busse et ai, 1988). ADO has also been 
shown to increase intracellular concentrations of Ca2+ through activation of 
other K+ channels (Mehrke & Daut, 1990). Recent work by Ray and Marshall 
(2006) has shed light on some of the confusion about which endothelial ADO 
receptors activate receptor-specific K+ channels for the production of NO. The 
authors measured the NO response to A^ and A2A receptor-specific 
antagonists alone and each in combination with large-conductance KCa. 
small-conductance KCa and KATP channel inhibitors. Briefly, this study showed 
that both large- and small-conductance KCa channels are crucial for A2A-
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mediated NO release and that Ai-mediated NO release is dependent on KATP 
channels (Ray & Marshall, 2006). 
There is strong evidence that Ai and A2A ADO receptors are involved in ADO-
mediated vasodilation and these receptors are dependent on KATP and Kca 
channels, respectively, for NO release. Figure 1 displays the remaining 
intermediate steps in ADO-mediated NO production. 
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Figure 1. Potential pathways for ADO-mediated NO production. A1 stimulated NO production in left 
endothelial cell, and A2A stimulated NO production in right cell (from Ray and Marshall (2006)). 
The figure above represents the pathways for A r and A2A-mediated NO 
release as proposed by Ray and Marshall (2006). Based on their findings and 
reports by others it is suggested that the cascade begins with Ai receptor 
stimulation initiating the opening of KATP channels resulting in K+ efflux, 
hyperpolarizing the membrane, which drives Ca2+ influx, hence increasing the 
intracellular concentration of Ca2+. The rise in intracellular Ca2+ may directly 
influence NO production (Dora et ai, 1997) via the Ca2+-calmodulin pathway 
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(Ray & Marshall, 2006). However, the Ca -calmodulin pathway does not 
involve phospholipase A2 (PLA2), the activity of which has been shown to 
increase with stimulation of AT receptors (Dickenson & Hill, 1997). PLA2 
cleaves cell membrane phospholipids, yielding arachidonic acid (AA) which 
stimulates cyclo-oxygenase (COX) to form PGI2. PGI2 functions in an 
autocrine manner acting on endothelial IP receptors coupled to adenylate 
cyclase (AC) which increases intracellular cAMP, stimulating PKA, which in 
turn causes phosphorylation and subsequent activation of eNOS. 
The proposed pathway for A2A-mediated NO production is somewhat less 
complicated. Ray and Marshall (2006) explain that previous studies have 
shown that A2A receptors are positively coupled to AC, and A^-stimulated 
release of NO is dependent on intracellular increases in cAMP, which could 
potentially stimulate PKA and directly phosphorylate eNOS. PKA stimulation 
would simultaneously activate KCa channels, and similar to A1-mediated NO 
release, K+ efflux, membrane hyperpolarization and Ca2+ influx would follow. 
The increased intracellular Ca2+ would subsequently activate eNOS and 
ultimately form and liberate NO. 
To our knowledge, there is only one study in humans that has evaluated the 
effects of endothelial released NO on ADO-induced vasodilation. Smits et al. 
(1995) used venous occlusion plethysmography to measure resting forearm 
blood flow response to graded ADO infusion both before and during L-NMMA 
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infusion. Before L-NMMA was infused, ADO produced a dose-dependent 
increase in forearm blood flow. ADO and L-NMMA together still increased 
forearm blood flow, however baseline blood flow was significantly decreased 
compared to measurements without L-NMMA. Additionally, the authors found 
that during infusion of either KATP or Kca channel blockers there was no 
attenuation of blood flow (Smits et al., 1995). This study, however, does not 
address how the pathway may be influenced during reactive or exercise 
hyperaemia, immediately post-exercise and during recovery. More work in 
humans needs to be conducted before judging whether or not this pathway is 
that by which ADO exerts its vasodilatory effects. 
Methodological Considerations 
As convincing as some of the evidence presented has been, there are 
important considerations to be taken into account before drawing any 
conclusions on the relative importance of specific autocoids for the control of 
muscle blood flow. Firstly, many studies, and others not included in this 
review, have been conducted using animal models. There has always been 
debate surrounding the use of animals and the generalizability of the results 
to humans. Due to the nature of this fundamental research, it is important to 
form a strong foundation of knowledge before attempting to measure 
cardiovascular parameters invasively in humans. In this regard, it is clear that 
elucidation of the regulatory factors in biochemical control of the human 
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circulation necessitates invasive procedures. It is important to acknowledge 
that results from isolated animal tissue or in-vivo animal models may not 
entirely reflect the processes occurring in the human organism due to 
differences between species and thus generalizability of regulatory 
mechanisms in healthy and various physiological states must be taken with 
caution. It is necessary for prevailing concepts generally accepted as dogma 
from studies in the animal model be experimentally borne out in human 
models. 
It is also important to consider different blood flow and vasodilator 
methodologies both in terms of sampling location and technique. Some 
studies measure concentrations of NO or ADO, for instance, in the blood 
(Ballard etal., 1987) or interstitial fluid (Hellsten et al., 1998). It is crucial to 
understand that these measurements are not the same, and therefore can not 
be compared. Furthermore, blood flow measurements can be taken at 
different levels of the vascular tree; for example large arteries such as the 
aorta, brachial and femoral arteries versus microvascular flow in skeletal 
muscle tissue and other vascular beds. Additionally, different studies will 
report values using different measurement techniques; ultrasound Doppler, 
dye-dilution and plethysmography are just a few to mention. Under 
pharmacological manipulation of the circulatory response, researchers have 
often used different drug doses and administered them in different manners; 
bolus injection versus constant infusion. The extent to which these studies 
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represent physiological conditions is a necessary interpretive consideration 
for drawing conclusions. These design-related differences between studies 
make it somewhat difficult to compare results. 
It has also been suggested that different types of exercise may produce a 
different pattern of flow within the vessel lumen and therefore would stimulate 
the endothelium differently (Green et al., 2005). This may also warrant careful 
consideration when comparing and drawing conclusions from previous 
studies, and would also be worth investigating in the future. 
Based on the evidence of redundancy that has been shown (Boushel et al., 
2002; Boushel & Kjaer, 2004), it would be worthwhile to continue this 
experimental approach and further clarify how vasodilator substances interact 
under different physiological conditions. Although this review concentrates 
principally on the interaction of ADO and NO, the recommendations for future 
research apply to investigations of all vasodilator/ agents. Interventions 
should be planned such that different design components, including metabolic 
state, vasodilatory substance availability, exercise intensity and timing, 
among other parameters, are manipulated and studied simultaneously. While 
much evidence points to a communicative process between the muscle and 
the vasculature for matching blood flow to muscle oxidative metabolic 
demand, how this is regulated remains elusive. Future studies in this area are 
of high priority. 
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Rationale 
Despite the wealth of knowledge that has been acquired over the last 
decades, there are still many unknowns concerning the regulation of blood 
flow during both resting and exercising states. We are now aware that there 
are many different substances which contribute to this complex phenomenon, 
for example ADO (Radegran & Calbet, 2001), NO (Joyner & Dietz, 1997), 
ATP (Ralevic & Bumstock, 1998), PGI2 (Duffy et a/., 1999), and EETs 
(Oltman etal., 1998), among others. Boushel etal. (2002) have also shown 
that there is an element of synergy and redundancy between vasodilators. 
The details of how this redundant system operates have yet to be elucidated, 
especially in humans. In fact, the specifics of the individual vasodilator 
substances' signalling pathways are not yet clear. 
As previously mentioned, researchers have proposed that a few of the 
substances known to induce vasodilation are, in reality, acting as second 
messengers or mediating the action of another vasodilator. It has been shown 
in rat aortic endothelium that ADO initiates a cascade of signals which 
ultimately leads to the production of NO (Ray & Marshall, 2006). This pathway 
has also been proposed to be that by which ADO exerts its vasodilatory 
effects. To our knowledge, this theory has only been tested once before in 
humans; this trial measured forearm blood flow only under resting conditions 
(Smitsefa/., 1995). 
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In addition, which of the local substances produced preserves a large portion 
of the blood flow response has not been clearly established in the literature. 
Furthermore, a great deal of work is still necessary in order to clarify any 
dependencies or interactions that many exist amongst vasodilator agents 
carried in blood, produced by vascular endothelium and smooth muscle as 
well as those potentially produced and released by adjacent skeletal muscle. 
This particular study was designed to investigate the role of ADO, NO and 
potential interactions between the two endogenously produced vasodilator 
substances in regulating skeletal muscle blood flow at rest and during 
exercise in humans. 
Specific Objectives & Hypotheses 
The first objective was to determine the blood flow response to combined 
ADO and L-NMMA infusion. We hypothesized that muscle blood flow would 
be lower in ADO+L-NMMA infusion when compared to ADO infusion alone 
supporting the concept that adenosine-induced vasodilation is partially NO 
mediated. Secondly, we sought to determine the magnitude of muscle blood 
flow responses to ADO infusion during exercise compared to the response to 
control exercise and exercise + ADO infusion. We hypothesized that the 
magnitude of blood flow during exercise + ADO would be similar to that of 
ADO infusion alone at rest, reflecting local autoregulation of blood flow during 
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exercise to match blood flow to metabolic demand. Thirdly, as has been 
previously shown in one study in human muscle, adenosine may play an 
important role in regulating blood flow distribution and dispersion linking blood 
flow to discrete motor unit activation. Therefore the third purpose of this study 
was to determine the role of ADO for regulating muscle blood flow 
heterogeneity. It was hypothesized that ADO infusion would result in 
increased blood flow heterogeneity in muscle reflecting local differences in 
ADO receptor sensitivity and/or density. Lastly, we collected muscle interstitial 
fluid by microdialysis in order to evaluate the concentration of the NO 
metabolite, nitrite, the concentration of ADO and any additional compensatory 
release of other vasodilator substances. It was hypothesized that muscle 
interstitial nitrite and ADO concentrations would increase during ADO infusion 
when compared to control conditions, and that nitrite would be reduced, but 
not ADO, during L-NMMA infusion. 
METHODS 
Participants 
Fourteen healthy subjects (13 men, 1 woman) participated in this study. 
Written informed consent was obtained from the participants after having 
been explained the purpose, nature and potential risks of the study. The 
project protocol was reviewed and approved by the Ethical Committee of 
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Copenhagen (H-KF-01-211/95) and the study was performed in accordance 
with the Declaration of Helsinki. Subjects were asked not to exercise, smoke 
or consume alcohol or caffeine within 24 hrs prior to testing. 
Exercise Protocol 
The study protocol is shown in Figure 2. Measurements were all performed 
on the same day for each individual participant. The participants were tested 
at rest and during exercise, each under 3 different conditions; control, ADO 
infusion (150 mg • kg body mass "1 #min"1) and combined L-NMMA (1 mg • kg 
body mass "1 'min"1) and ADO infusion. Based on experience, the dosage of 
ADO infused was selected to elicit a blood flow response similar to that 
expected during the exercise phase alone (exercise conditions described 
below). Each condition was 30 minutes in duration. The control, ADO infusion 
and combined infusion phases were divided into a 15 minute resting 
measurement period and 15 minutes of 1-leg knee extension exercise at 25 
Watts. During these collection periods, cardiac output and muscle blood flow 
measurements were taken at 5 and 10 minute time points. Interstitial fluid was 
collected for the entire duration of each phase. Prior to administering the 
combined infusion of ADO+L-NMMA, an L-NMMA primer of the same 
concentration was infused for 10 minutes. The total testing time was 
approximately 5 hours. 
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Arterial blood pressure was constantly monitored using a digital hospital 
monitoring system which recorded pressure from a transducer placed in the 
radial artery (Baxter Inc, USA) interfaced with a chart recording device 
(Powerl_ab/16SP model ML 795, ADInstruments, Colorado Springs, CO). 
Heart rate (HR) was determined from the on-line pressure wave recording. 
Microdialysis 
Prior to beginning instrumentation, thigh length, circumference and skinfolds 
were measured and used to estimate thigh volume and thigh muscle mass 
(Andersen & Saltin, 1985). The participants' skin, subcutaneous tissue and 
underlying muscle fascia was anaesthetised with 1 ml -1.5 ml of 1% 
lidocaine, followed by deep tissue perforation with an 18 gauge needle used 
to guide the insertion of the homemade (described below) or manufactured 
(CMA 63, CMA/Microdialysis AB, Solna, Sweden) microdialysis probes into 
the vastus lateralis (VL) muscle of the quadriceps group. Homemade 
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microdialysis probes were comprised of a 4-cm semipermeable membrane 
obtained from an artificial kidney dialysis machine (GFS 16-GFE 18; Gambro, 
Lund, Sweden) with a 20kDa cut-off, connected at either end to hollow nylon 
tubes. The VL muscles of both the exercising (right leg; 3 homemade and 2 
CMA probes) and control (left leg; 1 homemade and 1 CMA probe) legs were 
instrumented with microdialysis catheters. The homemade probes were 
inserted into the muscle at a depth of approximately 1 cm and the 
commercially-made CMA probes were inserted obliquely into the quadriceps 
muscle at a depth of 4 cm. All microdialysis probes were perfused at a rate of 
5 )Lilmin"1 with Ringer acetate solution (Pharmacia; Stockholm, Sweden) 
combined with micro-amounts of radioactive [14C] ethanol (Sigma, Missouri, 
USA) and [2-3H] Adenosine (GE Healthcare, Amersham, UK). The muscle 
was perfused at a constant rate throughout the entire duration of the testing 
day, including recovery periods. Dialysate was collected in capped microvials 
(CMA/Microdialysis AB, Solna, Sweden) and immediately frozen at -80°C. 
The dialysate samples will remain frozen until the time of analysis. 
Following insertion of the microdialysis probes, the participant rested for 90 
minutes, which has been shown to be sufficient to minimize any tissue 
response from the trauma resulting from the insertion of the microdialysis 
probe (Bangsbo, 1999; Langberg era/., 2002). During this time, the 
participant was instrumented with the necessary equipment for cardiac output 
and blood flow measurements. 
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Catheterization 
Under local anaesthesia ( 1 % lidocaine), the participants were instrumented 
with 3 catheters using the Seldinger technique; 2 arterial (femoral and radial 
arteries) and 1 venous (median antebrachial vein). Insertion of the arterial and 
venous catheters was, on all occasions, performed by a medical doctor. 
Cardiac Output Measurement 
Cardiac output was measured using the dye-dilution technique. As described 
by Dow (1956), this method is based on two concepts. Firstly, if dye is added 
at a constant rate to flowing blood, the rate of blood flow can be determined 
by the concentration of the dye which is equilibrated in downstream vessels 
by first passage and full mixing in the central venous and pulmonary 
circulations. Alternatively, when a known volume of dye is rapidly injected into 
any vein, the arterial accumulation of the injected dye over time will result in 
the quantification of the blood flow which has diluted it (Dow, 1956). Flow is 
then calculated by the following formula (Hamilton et a/., 1948): 
f=\_ Formula 1 
ct 
where /"is the flow in litres-second"1,1 is the amount of dye injected into the 
vein (mg), c is the average concentration of the dye for the duration of the 
curve (mg/L) and t is the duration of the curve in seconds. When using this 
technique in animal models, it is necessary to account for recirculation of the 
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dye (Figure 3). To do this, the down slope is extrapolated between points at 
approximately 75% to 50% of peak arterial dye concentration (Hamilton et al., 
1948; Boushel et al., 2000). The resulting constructed curve eliminates 
recirculation and thus allows for calculation of blood flow based on first 
passage of the dye. 
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Figure 3. Sample arterial curve. Tailing off of the recording represents recirculation of the injected dye. 
Extrapolation of the downslope (dashed line) of the arterial curve between the points denoted, 
representing 75% to 50% of peak arterial dye concentration, reconstructs the curve as though 
recirculation had not occurred. 
A bolus of indocyanine green (ICG) dye (ICG-Pulsion, Pulsion Medical 
Systems, Munich Germany) was quickly injected into the participants' 
antebrachial vein followed by a flush of saline (approximately 10 ml). 
Concomitantly, blood was drawn from the radial artery by an automated pump 
(Harvard Apparatus, Millis, MA, USA) at a rate of 20 ml/min through a linear 
photodensitometer (Waters CO-10. Instruments Inc., Rochester, MN, USA) 
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where a voltage signal, representing the light attenuation of the dye, was 
registered by a chart recorder (PowerLab/16SP model ML 795, 
ADInstruments, Colorado Springs, CO). The drawn blood was then re-infused 
into the median antebrachial vein in a close-looped aseptic system. At the 
end of each experiment, an ICG-voltage calibration curve was derived from 3 
samples of the participant's blood spiked with known volumes of ICG. Cardiac 
output was then calculated using the Formula 1. 
Microvascular Blood Flow Measurement 
Local blood flow in the exercising VL was measured by near infared 
spectroscopy (NIRS) using a NIRO 300 spectrophotometer (Hammatsu 
Photonics, Herrsching, Germany) in combination with bolus injections of ICG 
dye. This technique has been described in detail by Boushel et al. (2000). 
Two sets of receiving and emitting optodes were placed parallel to fiber 
direction of the VL muscle at proximal and distal positions. The paired 
optodes were separated by a distance of 40 mm, which corresponds to a light 
penetration depth of -25 mm. ICG dye was injected as previously mentioned 
for cardiac output measurements. 
The ICG bolus enters the venous circulation, travels to the right atrium then 
ventricle, through the pulmonary circulation and back to the left atrium and 
ventricle. After having passed though the cardio-pulmonary circulation, the 
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ICG is sufficiently mixed with the blood, and exits the heart into the arterial 
circulation, where the ICG dye in the muscle's microcirculatory beds (vessels 
<200um diameter) will eventually be detected by the NIRS optodes. The peak 
optimal absorption wavelength of indocyanine green dye (ICG) is 800nm. The 
light absorption of ICG was thus measured as molar value of light attenuation 
at the specific wavelengths; 775, 813, 850 and 913 nm using the Modified 
Beer-Lambert Law incorporating the molecular weight of ICG using a matrix 
operation programmed in Matlab. Muscle blood flow was then calculated as 
the ratio of ICG accumulation in the tissue to the average ICG concentration 
in the arterial blood over the same time frame (Boushel et al., 2000). The 
Sapirstein principle states that after bolus administration of a tracer, in our 
case ICG dye, for a certain period of time before reaching peak dye 
accumulation, the fraction of the tracer distributed to the tissue matches the 
fraction of cardiac output (otherwise considered the arterial input function in 
Formula 2) being delivered to the tissue (Sapirstein, 1956). Therefore, blood 
flow (ml blood • 100 ml tissue"1- min"1) can be calculated by the following 
formula: 
Blood Flow = K NCGIm f Formula 2 
of [ICG]a df 
where K is a constant for the conversion of ICG from units of moles to 
grams-L"1, [ICG]m is the accumulation of ICG in the muscle tissue (nmoles) 
over time t and J1 [ICG]a df is the time integral of the arterial concentration of 
ICG (mg-L-1) (Boushel et al., 2000). 
34 
Because the blood was injected into the venous system, we assume it was 
adequately mixed by the time it had passed though the pulmonary circulation 
and over to the left side of the heart before entering the systemic circulation. 
Thus ensuring the accumulated dye concentration and blood flow calculation 
should be indeed reflective of muscle blood flow. Also, because blood flow 
was calculated over a time interval less than that to reach peak ICG 
accumulation, the potential effects of dye recirculation in the muscle are 
negated. 
Statistical Analysis 
Power calculations were performed to determine sample size. Based on the 
literature in the field, a difference of 15% in blood flow was anticipated in 
order to establish significance. This resulted in a minimum of 10 subjects, 
whereas we initially recruited 14 in order to account for subject withdrawal. 
Due to incomplete data sets only 12 of the 14 initially recruited were used in 
the statistical analysis of the data. Values are presented as mean±SEM for all 
experiments and measurements. For all statistical evaluations, a P value of < 
0.05 was considered significant. Statistical analysis of differences in HR, 
MAP, SV and CO comparing between rest vs. exercise and conditions were 
carried out with a two-way repeated measures ANOVA. Because it has been 
well established that blood flow will significantly increase when shifting from a 
resting to exercising state, the data has been divided accordingly and the 
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blood flow analysis was simplified to a two-way repeated measures ANOVA 
treating condition and optode position as manipulated factors investigated. 
The oxygenation data was also analysed using a two-way repeated measures 
ANOVA in addition to regression analysis to determine a time constant for the 
attenuation of ADO dilation. In the case of a significant main effect and 
interaction between variables, the Holm-Sidak method was used for post-hoc 
analysis. SigmaPlot version 11.0 (Systat Software Inc., San Jose, CA, USA) 
was used for all computational analyses. 
RESULTS 
Subjects 
Table 1 below displays the participant characteristics for the 12 subjects who 
were included in the analysis. 
Characteristic Mean ± SE 
Age(yr) 24.1 ± 1.2 
Weight (kg) 78.3 ± 3.9 
Height (cm) 182.3 ± 2.0 
BMI(kg/m2) 23.5 ± 1.0 
Thigh Volume (L) 9.25 ± 0.6 
Muscle Mass (kg) 8.81 ± 0 . 6 -
Table 1. Subject Characteristics. Values are Mean ± SE (N=12); 




Heart rate (HR) significantly increased between rest and exercise states 
under control (65.6±2.2 - 84.9±3.5 bpm, P<0.001), ADO infusion (79.5±2.7 -
95.2±3.7 bpm, P<0.001), and ADO+L-NMMA infusion (74.5+3.4 - 86.8±5.3 
bpm, P<0.01). See Figure 4.A. Moreover, at rest HR was significantly higher 
(P<0.001) during ADO and ADO+LNMMA infusions (79.5±2.7 and 74.5±3.4 
bpm, respectively) when compared to control (65.6±2.2 bpm). At rest, mean 
arterial pressure (MAP) was only significantly increased during ADO+L-
NMMA infusion when compared to control (104.9±1.8 vs. 94.1 ±2.6 mmHg, 
P<0.01). No other differences in MAP were observed between conditions at 
rest (Figure 4.B). Stroke volume (SV) remained unchanged between 
conditions at rest (Figure 4.C). CO during ADO infusion was significantly 
increased when compared to control at rest (9.1 ±1.1 vs. 6.8±0.8 L • min"1, 
P<0.01) (Figure 4.D). There was no significant difference between other 
conditions. 
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ADO + L-NMMA 
Figure 4. Systemic parameters at rest. (A) Heart rate (B) Mean arterial pressure (C) Stoke volume 
and (D) Cardiac output measurements at rest during; control (CTRL), ADO infusion (ADO) and ADO+L-
NMMA infusion (ADO+L-NMMA). *Value different from CTRL, P< 0.05; "Value different from ADO, P< 
0.05. 
Exercise 
During exercise, HR was greater in ADO compared to control (95.2+3.7 vs. 
84.9±3.5 bpm, PO.001) and compared to ADO+L-NMMA infusion (86.8+5.3 
bpm, P<0.01); however no differences were seen between control and 
ADO+L-NMMA infusion during exercise (Figure 5.A). MAP did not differ 
between conditions during exercise; however exercising MAP during control 
and ADO infusion were found to be higher compared to these same 
conditions at rest (see Figure 5.B). SV remained unchanged. Comparison 
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between SV during rest and exercise for each condition showed no 
differences (Figure 5.C). CO was higher during exercise for each of condition 
when compared to the same condition at rest. CO during ADO infusion was 
significantly increased when compared to control during exercise (10.8±0.8 
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Figure 5. Systemic parameters during exercise. (A) Heart rate (B) Mean arterial pressure (C) 
Stoke volume and (D) Cardiac output measurements at rest during; control (CTRL), ADO infusion 
(ADO) and ADO+L-NMMA infusion (ADO+L-NMMA). * Value different from CTRL, P< 0.05; ** Value 
different from ADO, P< 0.05; # Value different from rest, P< 0..05. 
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Blood Flow 
There was no statistical difference between blood flow values calculated for 
the first (5 minute) and second (10 minute) measurements; therefore the time-
dependent data was averaged resulting in a mean blood flow value over the 
testing periods. It has been well established that blood flow will significantly 
increase when shifting from a resting to exercising state, and so the data has 
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Figure 6. Proximal vs. distal blood flow. (A) VL blood flow measured at rest for both proximal (solid 
bars) and distal (dotted bars) measurement sites. (B) Blood flow measured in VL during 1-leg knee 
extension exercise; proximal (solid bars) and distal (dotted bars). * Value different from CTRL, P< 0.05; 
** Value different from ADO, P< 0.05; # Value different from rest, P< 0.05. 
There were no differences in blood flow found between optode locations (i.e. 
no difference between proximal vs. distal measurements) either at rest or 
exercise for any of the prescribed conditions (control, ADO, ADO+L-NMMA). 
Blood flow was significantly increased with ADO infusion when compared to 
control at rest (proximal: 63.7±12.4 - 9.9±1.7 mMOOml tissue"1 .•min"1, 
p<0.001; distal: 55.6±13.1 -7.0+.1.7 mMOOml tissue"1 •min"1, p<0.001)and 
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during exercise (proximal: 135.6±23.5 - 56.7±9.0 mMOOml tissue1 'min1, 
p<0.001; distal: 126.7±14.6 - 55.8±7.0 mMOOml tissue'"•min"1, p<0.001). The 
same pattern of significance was observed between ADO+L-NMMA infusion 
and control for both proximal and distal VL at rest and exercise (see Figure 
6). Interestingly, there was a significant decrease in blood flow during 
exercise, for both the proximal and distal VL, when L-NMMA infusion is 
superimposed on ADO infusion (p<0.01). Additionally, by design, blood flow 
values during ADO infusion at rest and exercise alone are quite similar in 
magnitude (see 'Experimental Protocol' in Methods section). 
To further investigate the effects of the prescribed conditions, the blood flow 
data for the 2 measurement sites was pooled, generating a mean blood flow 
value over time for the VL muscle during testing under each prescribed 
condition. What we see here is that there is a significant difference of mean 
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EXERCISE 
Figure 7. Mean VL blood flow at rest and during exercise. Pooled VL blood flow measured at rest 
(solid bars) and during 1-leg knee extension exercise (dotted bars). * Value different from CTRL, P< 
0.05; ** Value different from ADO, P< 0.05; # Value different from rest, P< 0.05. 
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Vascular Conductance 
Vascular conductance (VC; calculated as: blood flow/MAP) increased 
between control and ADO infusion (P<0.05) and between control and ADO+L-
NMMA infusion (P<0.05). The same observations were made during exercise. 
Moreover, VC is significantly increased when comparing between rest and 
exercise for each of the conditions, respectively (Figure 8). 
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Figure 8. Proximal vs. distal vascular conductance at rest and during exercise. (A) Vascular 
conductance calculated at rest for both proximal (solid bars) and distal (dotted bars) measurement sites. 
(B) Vascular conductance during 1-leg knee extension exercise for proximal (solid bars) and distal 
(dotted bars). * Value different from CTRL, P< 0.05; ** Value different from ADO, P< 0.05; # Value 
different from rest, P< 0.05. 
Tissue Oxygenation 
The oxygenation data are expressed as the absolute change in 
oxyhemoglobin concentration ([02Hb]) with all measurements normalized to 
baseline concentration. When comparing [02Hb] between proximal and distal 
measurement sites, significant differences were noted at peak concentration 
(p<0.05) and at 2 minutes post-peak (p<0.05). Additionally, a clear time 
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attenuation effect of adenosine was seen from the peak response over the 
subsequent 5 min (Figure 9). 
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Figure 9. A [02Hb] with ADO infusion at rest. * Value different from measurement at previous time point, 
P< 0.05; § Values significantly different between proximal and distal measurements, P< 0.05. 
DISCUSSION 
The key findings in this study were that 1) ADO-mediated muscle vasodilation is 
mediated in part by NO in humans, 2) ADO infusion does not generate muscle 
blood flow heterogeneity in muscle at rest or during exercise, 3) the time course 
of ADO-induced vasodilation reaches an immediate peak response followed by a 
gradual attenuation over the course of the next 5 minutes and 4) ADO infusion 
overrides local autoregulatory blood flow control mechanisms during exercise 
resulting in an exaggerated blood flow response to muscle contraction and an 
overperfusion of muscle relative to metabolic demand. 
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Role of NO in ADO-induced Vasodilation 
In this study, we found that there is a significant increase in blood flow at both 
rest and exercise when ADO is infused, compared to control conditions. 
Additionally, the results show that the infusion of ADO combined with L-NMMA at 
rest and during exercise elicits blood flow values lower than those observed with 
ADO infusion alone, however blood flow is still significantly higher than the 
control condition. Essentially, when taken together, these findings demonstrate 
that there is some involvement of NO in the pathway whereby ADO regulates 
vascular tone. These findings support our main hypothesis and corroborate the 
results of work done in animals as discussed previously in the literature review 
(Ray & Marshall, 2006). 
Based on previous studies using similar doses of NO blockade as that 
administered in this study, it can be deduced that approximately 60-70% of NOS 
enzyme activity was collectively inhibited. Frandsen et al. (2000) measured 
skeletal muscle NOS activity ex-vivo under systemic pharmacological blockade 
of NOS with L-NAME and found a 60-70% reduction in NOS activity. Lattereur et 
al. (In preparation) found a similar 60% lower interstitial concentration of nitrite 
during blockade of NO with L-NAME administered directly into contracting 
muscle through a microdialysis probe via infusate solution. In the present study, 
we found decreases in blood flow between ADO and ADO+LNMMA infusion 
across the muscle ranging between 35-47% at rest, and 23-30% decrease during 
exercise. Therefore, while a significant measurable portion of ADO-mediated 
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vasodilation is clearly triggered by secondary pathways involving NO formation, 
this value may be an underestimation of the full contribution of NO to this 
pathway. The precise magnitude of the NO component of vasodilation imparted 
by endogenous adenosine release under control exercise cannot be estimated 
from the current data set. However it is with certainty that these vasodilators 
function in a synergistic manner to regulate blood flow in humans in-vivo. 
It is important to acknowledge endothelial-dependent NO production as a 
contributor to muscle vasodilation, which ultimately influences blood flow. 
Because ADO is known to be a powerful vasodilator, eliciting blood flow values 
seen at peak exercise with infusion under resting conditions (Radegran & 
Hellsten, 2000), sudden and significant increases in blood flow, such as that 
brought upon with ADO infusion, likely causes an increase in the level of shear 
stress imposed on the inner luminal wall of any conduit vessel. Furthermore, the 
resulting increased shear-stress on the endothelial lining is known to initiate an 
intracellular cascade resulting in augmented production of endothelial-dependent 
NO. In several studies solely investigating shear stress and its influence on blood 
flow it has been shown that the endothelial-dependent NO component of shear 
stress lasts for the first 5 minutes of stimulus (using a cuff-occlusion model) 
(Pyke & Tschakovsky, 2005). In the context of the present study, if shear stress 
influences endothelial-dependent NO production then consequential vasodilation 
would be negligible after 5 minutes of stimulus (i.e. pharmacological agent 
infusion), then all blood flow measurements recorded following the initial 5 
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minutes of infusion (as with our study; 5 and 10 minutes) will reflect only the 
influence of the prescribed conditions (i.e. CTRL, ADO infusion, ADO+L-NMMA 
infusion). We can be certain that the second blood flow measurement taken at 10 
minutes was well beyond the time frame in which endothelial-derived NO exerts 
its influence on vascular tone via a shear stress effect. Furthermore, because 
there was no statistically significant difference between the first (5 minute) and 
second (10 minute) recordings then it can be inferrred that if in fact a shear-
induced response was elicited, there was little or no residual influence at the time 
of the first blood flow measurement, which supports the '5 minute rule' as 
suggested by Pyke and Tschakovsky (2005). Thus, all of the blood flow values 
reported do in fact solely reflect the impact of the pharmacological interventions 
on blood flow, entirely negating the influence of shear stress. 
Most recently, Ray and Marshall (In press-b) investigated the reverse pathway; 
whether or not de novo synthesis of NO required for the release of adenosine. In 
that study in rats, a series of pharmacological interventions were applied to 
elucidate the role of adenosine in muscle blood flow regulation. During adenosine 
receptor blockade by either an Ai or A2A selective pharmacological agent, it was 
found that muscle blood flow during electrically evoked muscle contractions was 
significantly attenuated. The lower blood flow during contraction was observed 
primarily with ZMA225 blockade of the A2A pathway. No further reduction in blood 
flow was seen with L-NMMA superimposed on the ZMA225 A2A induced 
reduction in blood flow. To further confirm that NO was not necessary for the 
endogenous release and downstream vasodilating effect of adenosine, the 
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intracellular NO donor 8-bromo cGMP was also administered to increase NO 
levels, bypassing the NOS blockade effect of L-NMMA, and again no differences 
in blood flow were observed. It was clearly demonstrated that unlike the 
dependence of NO for adenosine mediated vasodilation as shown in reverse in 
the present study, the presence of NO is not necessary for the 'generation' of 
adenosine during muscle contraction. This is supported by previous work which 
showed that during NOS blockade with L-NAME (Frandsen etal., 2000) and 
combined blockade of NOS and cyclooxygenase by L-NAME and indomethacin 
(Boushel et al., unpublished results), respectively, there is no compensatory 
increase in adenosine production measured in the interstitium of muscle tissue. 
Based on the significant differences observed between muscle blood flow values 
with ADO infusion and ADO+L-NMMA infusion, the data support NO as a 
mediator within the ADO-initiated vasodilation cascade. The extent to which NO 
is involved in ADO signaling system remains to be elucidated. 
Role of ADO in Muscle Blood Flow Heterogeneity 
It is still not clear whether or not ADO does indeed play a role in heterogeneous 
distribution of blood flow across a vascular bed feeding skeletal muscle. There is 
a lack of consistency among the results from studies looking specifically at this 
question which further complicates the interpretation of the outcomes of the 
current study. If we consider the 2 different regions of the muscle from which we 
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recorded (proximal vs. distal) at any of the levels of condition (i.e. CTRL, ADO, 
ADO+LNMMA.) there is no evidence to support a role for ADO in regulating 
blood flow heterogeneity. 
As previously mentioned, ADO receptors, namely A-i, A2A and A2B, have been 
localized to skeletal muscle vasculature (Lynge & Hellsten, 2000) and ADO is 
locally produced in close proximity to the extracellular space adjacent to 
endothelial cells (Clifford & Hellsten, 2004). These 2 factors have strongly 
contributed to the appreciation of ADO as a vasodilator. However, to be able to 
consider ADO as a factor involved in regulating the distribution of blood flow 
(whether it be heterogeneous or not), it is important to take into account the 
pattern of ADO receptor density across a vascular bed. Knowing whether or not 
one ADO receptor subtype is more dominant in terms of density and affinity, and 
whether the dispersion of these receptors is uniform within the muscle 
vasculature will contribute to understanding the capacity of ADO to control blood 
flow distribution. To date, there is no single study to our knowledge that has 
directly investigated this question of receptor density specifically in human 
skeletal muscle and its vasculature. However, one recent study evaluated ADO 
receptor density in the myocardial microvasculature (Heinonen etal., 2008). A2A 
receptor volume was found to be much higher in the myocardium of trained 
athletes compared to untrained controls. When expressed per unit of myocardial 
mass there was no difference between trained and untrained. Importantly, it was 
concluded that as the blood flow demands of a trained heart capable of a 70% 
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larger cardiac output, a relatively higher cardiac work capacity and increased 
oxygen demand, adenosine receptors known to vasodilate the coronary 
vasculature were proportionately increased in their expression. A significant 
secondary conclusion was that the trained heart had a luxury (excess) blood flow 
per unit heart work which raises the question of vasodilator receptor sensitivity 
and kinetics. This area of research merits further investigation. 
Recent reports evaluating the contribution of ADO to blood flow heterogeneity 
from a physiological perspective have yielded conflicting results. Heinonen et al. 
(2007) measured blood flow in the 4 compartments (vastus lateralis, medialis, 
intermedius and rectus femoris) of the quadriceps femoris muscle group during 
rest and 3 levels of incremental exercise (1-leg knee extension) without and then 
with non-selective ADO receptor blocking agent, theophylline. Interestingly, the 
authors observed a decrease in blood flow heterogeneity corresponding to 
increasing exercise workload both with and without theophylline; however overall 
and individual muscle blood flow levels increased. Ultimately, the authors 
concluded that ADO may have a role in contributing to blood flow heterogeneity 
at low to moderate levels of exercise. 
On the basis of the above mentioned and other recent studies employing 
positron emission tomography using radioactive isotope tracers and magnetic 
resonance imaging, there is evidence that within a contracting limb, the 
magnitude of blood flow to discrete regions of muscle is not homogenous 
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(Mizuno etal., 2003; Heinonen etal., 2007). Extending upon earlier studies 
which have demonstrated a close matching between muscle metabolic demand 
and oxygen delivery to limbs engaged in contraction (Andersen & Saltin, 1985), a 
current avenue in research is to identify how this close matching is regulated. 
In the current study, several factors may contribute to the less than robust 
differences in blood flow heterogeneity observed. Firstly, with prolonged 
exercise, even at low intensities additional muscle fibers will be recruited in order 
to continue the exercise task (Ray & Dudley, 1998). These secondarily recruited 
fibers require blood flow supply to be increased so as to support their elevated 
metabolic state (Ray & Dudley, 1998). Hence, it could very well be that the time 
points at which blood flow measurements were recorded in our study were 
beyond this point of secondary muscle fiber recruitment and blood flow had 
already leveled out across the muscle. 
Furthermore, with the ADO infusion superimposed on exercise, it is possible to 
have saturated the ADO receptors with the dose given, at which point the 
receptor activity would be the limiting factor in further dilating the blood vessels. 
Along these same lines, it is possible that there is a threshold ADO 
concentration, at which this autocoid would no longer act to extend vasodilation. 
Further investigation is warranted. 
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At low exercise intensities such as that prescribed in our protocol, it is possible to 
meet the metabolic demands of the tissue by means of increasing oxygen 
extraction and not necessarily increasing the amount of blood delivered to the 
tissue (Boushel et al., 2002; Mortensen et al., 2007). This may be the case in the 
present study. Differences observed between proximal and distal Hb02 reflect 
differences in metabolic demand between the two sites. However, the data did 
not reflect any differences when comparing blood flow measured at the two sites. 
Therefore, if blood flow was not enhanced, then there must exist another system 
which acts to supply the active tissue with adequate quantities of O2 to be able to 
sustain exercise. Thus, even though we observed a metabolic heterogeneity, 
there was no blood flow heterogeneity because potentially another mechanism, 
which we suspect is an increase 0 2 extraction, was able to maintain a sufficient 
level of 0 2 availability for the active tissue. 
It has been suggested that with L-NMMA blockade of NOS, changes in blood 
flow seen during exercise may be the result of decreased basal flow and not 
necessarily due to an interaction between NO and exercise (Endo et al., 1994). 
Prior to beginning the combined infusion of ADO+L-NMMA, we infused a 10 
minute primer of L-NMMA so as to ensure NOS was indeed blocked. However, in 
accordance with the findings of Endo et al. (1994), we likely decreased baseline 
blood flow, and may have therefore confounded the findings. Throughout the 
time elapsed during the L-NMMA primer infusion, it is possible that the lack of 
NO being produced as a result of the NOS blockade was 'sensed' in some 
manner by the redundant/synergistic vasodilators/systems and thus, additional 
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vasodilating agents were recruited in a compensatory fashion so as to counteract 
the lack of vasodilation usually maintained by available NO. 
Time Course of ADO-mediated Muscle Vasodilation 
Immediately following the initiation of ADO infusion into the femoral artery during 
resting conditions, the muscle tissue [02Hb] significantly increased and reached 
a peak concentration within 1.5-2 minutes. Subsequently, a gradual decline was 
observed over the 5 minutes following the point of peak concentration, after 
which the [02Hb] was stable; however still elevated above baseline values. To 
our knowledge, this is the first time this phenomenon has been reported with 
ADO infusion. 
It is reasonable to speculate that during this initial phase of infusion part of the 
observed trend would result from the sudden surge of increased endothelial-
dependent NO production resulting from the increase shear stress brought on by 
ADO infusion; however, it is not possible that it is exclusively a shear-induced 
reaction. Without doubt, there will be some contribution of ADO and the vaso-
active substances, with which ADO interacts, in addition to non-endothelial-
dependent NO formation. 
There are numerous factors which may contribute to the [Hb02] response 
observed. Of great interest and importance is the ensuing decline in the [Hb02]. 
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Why is it that with a constant rate of ADO infusion, and constant metabolic 
demand (rest), the [Hb02] is not maintained at the peak (or close to peak) levels 
throughout the duration of infusion? Unfortunately, we are unable to answer this 
question based on the evidence collected during this study; however, we propose 
3 explanations for this occurrence; 1) desensitization of the local ADO receptors; 
2) redistribution of blood flow as a result of opening of new capillary beds; 3) 
attenuation of reflex neural signals. It is quite possible that the ADO receptors 
can become desensitized and thus less responsive to the available exogenous 
ADO when exposed to supranormal levels of exogenous ADO. Additionally, there 
could be secondary opening of new capillary beds as a consequence of the 
assault on the initially dilated regions with the overwhelming and immediate 
increase in flow. Because the metabolic demands of the tissue have remained 
unchanged (always at rest during this period), there was no need for the excess 
blood flow being delivered to the muscle regions. Local signals and adjacent 
networks (activated neurally or from spillover) may have acted to redirect the 
excess flow to new muscle regions and therefore decreasing [Hb02] in the 
initially over-supplied regions. A reflex signal at the time of initial infusion with 
input to the ventrolateral medulla to evoke increases in blood flow (apart from 
any local effects) may also be a factor since subjects reported sensations that 
coincided with the observed rapid increase in Hb02. Additional research is 
necessary to support these suggestions. 
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Influence of ADO on Muscle Autoregulation of Blood Flow 
Skeletal muscle tissue and its vasculature have the ability to locally regulate 
blood flow to match metabolic demands (Andersen & Saltin, 1985). From the 
control data during exercise, we see that muscle tissue blood flow is increased to 
approximately 60 mMOOml tissue"1*min"1. Interestingly, we see that with the 
same metabolic perturbation (i.e. 1 -leg knee extension exercise at 25W) blood 
flow by far exceeds the amount necessary to carryout the prescribed activity. 
There is a significant excess flow when ADO infusion is superimposed onto 
exercise clearly showing that the tissue has a massive stimulated blood flow 
reserve. When L-NMMA infusion is added, we still see an excess of flow to the 
microcirculation. What exactly might cause the ADO infusion to override local 
autoregulatory mechanisms is unknown. 
Limitations 
As with any scientific undertaking, our study design and measurement 
techniques do impose certain limitations on the interpretation of the results. 
Firstly, while blood flow differences between infusion conditions were found, we 
cannot confirm the extent to which NO is implicated in ADO-mediated 
vasodilation because 1) L-NMMA does not block all NOS activity and 2) a dose-
dependent response needs to be shown in order to establish the strength of 
association between NO and ADO induced vasodilation. However, the use of a 
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repeated measures design, by nature, decreases the inter-participant biological 
variability and hence the final analyses are more robust. Also, when using the 
NIRS-ICG technique to quantify blood flow, it is necessary to acknowledge that 
within the recorded signal, there is some contribution of skin blood flow, although 
minimal. There is still some debate about what the optimal optode distance is so 
as to avoid recording signals from the skin and underlying adipose tissue 
(Quaresima & Ferrari, 2002; Ferrari etal., 2006). Also, the NIRS-ICG technique 
in and of itself is quite invasive, costly and requires a great deal of experience in 
performing the technique. However, it is unique in that microvascular blood flow 
can be measured during exercise, where as other techniques do not have such 
high spatial and temporal resolution and only flow in major conduit arteries can 
be assessed. Additionally, imaging techniques cannot be used with an exercise 
model because it is important for the subject to remain still in order obtain the 
best quality image possible. Thus while the techniques employed in this study do 
have some limitations, there are indeed many advantages to using them. 
Future Directions 
Vascular research has come a long way in the last decades. However, a great 
deal of information has yet to be uncovered. Perhaps the most significant 
development in recent times is the concept and acknowledgement of 
redundancy/synergy between systems and locally produced chemicals regulating 
vasodilation. The challenge for future studies investigating the control of vascular 
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tone, especially in exercise hyperemia, is to continue to be innovative in the 
approach with which hypotheses are tested. Development of new vasodilator 
blocking or donating agents will be an important advancement in the field. 
Varying study designs by using different combinations of blockers and donors 
and varying the order in which they are administered is an example of how to 
manipulate the experimental setup to approach the same question from a slightly 
different angle. 
When considering the future of the ADO-mediated vasodilation pathway 
specifically, it will be necessary to learn more about the different receptors, their 
distribution and sensitivity within skeletal muscle tissue and vasculature from a 
reductionist perspective. It will also be important to demonstrate a dose-
dependent effect between ADO and NO in order to confirm with certainty, and 
measure to what extent the ADO-initiated vasoactive pathway is mediated by 
NO. 
Conclusions 
In summary, the major findings of this study were that 1) ADO-mediated muscle 
vasodilation is mediated in part by NO in humans, 2) ADO infusion does not 
generate blood flow heterogeneity in muscle at rest or during exercise, 3) the 
time course of ADO-induced vasodilation reaches an immediate peak response 
followed by a gradual attenuation over the course of the next 5 minutes and 4) 
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ADO infusion overrides local autoregulatory blood flow control mechanisms 
during exercise, resulting in an exaggerated blood flow response to muscle 
contraction and an overperfusion of muscle relative to metabolic demand. 
While this work does help to shed light on a very complex question, a great deal 
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